Q4 2024 Earnings Call Feb 11, 2025, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participant ...
Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Cognizant has announced an expansion of its longstanding relationship with biopharmaceutical leader Gilead Sciences that aims to unlock even greater value for Gilead as it advances innovations to ...
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...
The trial, conducted in partnership with Gilead Sciences ... we post on the social media channels listed on our investor relations website.
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HI ...
Ladies and gentlemen, welcome to the Cognizant Technology Solutions’ Fourth Quarter 2024 Earnings Conference Call. All lines ...
HotelTechReport.com each year to make informed technology purchasing decisions. The HotelTechAwards determines the best hotel software products across every category based on customer feedback and ...
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with metastatic castrate-resistant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback